DK3497086T3 - Aminopyrimidin-SSAO-inhibitorer - Google Patents

Aminopyrimidin-SSAO-inhibitorer Download PDF

Info

Publication number
DK3497086T3
DK3497086T3 DK17838647.0T DK17838647T DK3497086T3 DK 3497086 T3 DK3497086 T3 DK 3497086T3 DK 17838647 T DK17838647 T DK 17838647T DK 3497086 T3 DK3497086 T3 DK 3497086T3
Authority
DK
Denmark
Prior art keywords
aminopyrimidine
ssao inhibitors
ssao
inhibitors
aminopyrimidine ssao
Prior art date
Application number
DK17838647.0T
Other languages
English (en)
Inventor
David Andrew Coates
Luo Heng Qin
Yi Wei
Jingye Zhou
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3497086T3 publication Critical patent/DK3497086T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK17838647.0T 2016-08-12 2017-08-04 Aminopyrimidin-SSAO-inhibitorer DK3497086T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2016/094833 WO2018027892A1 (en) 2016-08-12 2016-08-12 Amino pyrimidine ssao inhibitors
PCT/CN2017/095999 WO2018028517A1 (en) 2016-08-12 2017-08-04 Amino pyrimidine ssao inhibitors

Publications (1)

Publication Number Publication Date
DK3497086T3 true DK3497086T3 (da) 2022-03-14

Family

ID=61161335

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21206067.7T DK3984996T3 (da) 2016-08-12 2017-08-04 Aminopyridin-SSAO-inhibitorer
DK17838647.0T DK3497086T3 (da) 2016-08-12 2017-08-04 Aminopyrimidin-SSAO-inhibitorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK21206067.7T DK3984996T3 (da) 2016-08-12 2017-08-04 Aminopyridin-SSAO-inhibitorer

Country Status (22)

Country Link
US (3) US10287270B2 (da)
EP (3) EP3497086B1 (da)
JP (2) JP7035013B2 (da)
KR (3) KR102646063B1 (da)
CN (2) CN108884056B (da)
AU (2) AU2017309199B2 (da)
CA (1) CA3033687A1 (da)
CR (1) CR20190124A (da)
DK (2) DK3984996T3 (da)
ES (2) ES2992165T3 (da)
HU (1) HUE058142T2 (da)
IL (1) IL264745B (da)
MA (1) MA45937A (da)
MX (1) MX389672B (da)
MY (1) MY196576A (da)
NZ (1) NZ750290A (da)
PH (1) PH12019500296A1 (da)
PL (2) PL3984996T3 (da)
PT (1) PT3497086T (da)
SG (1) SG11201900844UA (da)
WO (2) WO2018027892A1 (da)
ZA (2) ZA201901097B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
JP7337174B2 (ja) 2018-09-18 2023-09-01 ニカング セラピューティクス, インコーポレイテッド Srcホモロジー-2ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
CN110938059A (zh) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) * 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
CA3112510A1 (en) * 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
JP7425793B2 (ja) * 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
TWI835945B (zh) * 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
AU2020206477B2 (en) * 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
MX2022005199A (es) 2019-10-29 2022-08-04 Eccogene Shanghai Co Ltd Inhibidores de ssao y uso de los mismos.
CN113149957A (zh) * 2020-01-23 2021-07-23 轶诺(浙江)药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
BR112022019168A2 (pt) * 2020-03-25 2022-11-01 Terns Inc Tratamento de distúrbios respiratórios
WO2021231644A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
PE20231096A1 (es) * 2020-08-25 2023-07-18 Lilly Co Eli Polimorfos de un inhibidor de ssao
CN114621243B (zh) * 2020-12-14 2024-03-01 上海拓界生物医药科技有限公司 一种磺酰胺类衍生物及其用途
KR20220145981A (ko) * 2021-04-22 2022-11-01 주식회사유한양행 트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물
AU2022387121A1 (en) * 2021-11-11 2024-06-20 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
US20230181583A1 (en) * 2021-11-11 2023-06-15 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
WO2008123469A1 (ja) * 2007-03-30 2008-10-16 Japan Tobacco Inc. 6員環アミド化合物およびその用途
WO2009012573A1 (en) * 2007-07-20 2009-01-29 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8426587B2 (en) 2007-11-21 2013-04-23 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
JP2011136942A (ja) * 2009-12-28 2011-07-14 Kowa Co 新規な置換ピリミジン誘導体およびこれを含有する医薬
KR101879011B1 (ko) 2011-03-15 2018-07-16 아스테라스 세이야쿠 가부시키가이샤 구아니딘 화합물
CA2871793C (en) * 2012-05-02 2020-09-15 Pharmaxis Ltd. Substituted 3-haloallylamine inhibitors of ssao and uses thereof
EA201590953A1 (ru) * 2012-11-16 2015-08-31 Бристол-Майерс Сквибб Компани Пирролидиновые модуляторы gpr40
US8962641B2 (en) * 2013-04-17 2015-02-24 Boehringer Ingelheim International Gmbh Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
WO2014184104A1 (en) * 2013-05-17 2014-11-20 Boehringer Ingelheim International Gmbh Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors

Also Published As

Publication number Publication date
PT3497086T (pt) 2022-03-14
EP3984996B1 (en) 2024-10-09
EP3497086B1 (en) 2021-12-15
EP4501323A2 (en) 2025-02-05
SG11201900844UA (en) 2019-02-27
NZ750290A (en) 2022-09-30
US20190276436A1 (en) 2019-09-12
JP2019527717A (ja) 2019-10-03
MY196576A (en) 2023-04-19
EP3984996A1 (en) 2022-04-20
MX2019001581A (es) 2019-06-20
CR20190124A (es) 2019-05-13
EP4501323A3 (en) 2025-03-19
AU2017309199B2 (en) 2022-05-12
WO2018027892A1 (en) 2018-02-15
KR20190038580A (ko) 2019-04-08
BR112019002275A2 (pt) 2019-06-18
ES2908805T3 (es) 2022-05-04
US20200262817A1 (en) 2020-08-20
DK3984996T3 (da) 2024-10-21
EP3497086A1 (en) 2019-06-19
JP7035013B2 (ja) 2022-03-14
PL3984996T3 (pl) 2025-03-10
CN114380801B (zh) 2025-07-29
PH12019500296A1 (en) 2019-05-15
AU2022203071B2 (en) 2024-06-20
US10287270B2 (en) 2019-05-14
IL264745B (en) 2021-08-31
CA3033687A1 (en) 2018-02-15
ES2992165T3 (es) 2024-12-09
ZA201901097B (en) 2022-08-31
KR20230008889A (ko) 2023-01-16
KR20240035917A (ko) 2024-03-18
KR102646063B1 (ko) 2024-03-12
AU2022203071A1 (en) 2022-05-26
AU2017309199A1 (en) 2019-02-21
US20180297987A1 (en) 2018-10-18
CN114380801A (zh) 2022-04-22
CN108884056A (zh) 2018-11-23
MA45937A (fr) 2019-06-19
HUE058142T2 (hu) 2022-07-28
MX389672B (es) 2025-03-20
US10793552B2 (en) 2020-10-06
JP7372957B2 (ja) 2023-11-01
CN108884056B (zh) 2022-01-07
JP2022003049A (ja) 2022-01-11
WO2018028517A1 (en) 2018-02-15
KR102483876B1 (ko) 2023-01-03
EP3497086A4 (en) 2020-03-25
PL3497086T3 (pl) 2022-05-02
ZA202202097B (en) 2023-11-29
US10464928B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
FIC20240013I1 (fi) Lebrikitsumabi
IL269196A (en) Novel inhibitors
IL263586A (en) Inhibitors of the menin-mll interaction
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
IL280863A (en) Autotaxin inhibitors and uses thereof
EP3626699A4 (en) SSAO INHIBITOR
DK3984996T3 (da) Aminopyridin-SSAO-inhibitorer
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
LT3303334T (lt) Tirozinkinazės inhibitoriai
EP3522831C0 (en) NEO-PHALLUS IMPLANT
PL3657060T3 (pl) Zacisk
DK3571192T3 (da) Jak1-selektive inhibitorer
LT3371171T (lt) Ret inhibitoriai
EP3440949A4 (en) FLAVOR INHALER
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
EP3347008A4 (en) BETA-Lactamase INHIBITORS
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
DK3341379T3 (da) EZH2-hæmmere
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3402423C0 (fr) Dispositif d'implant
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases